
Divis Laboratories Sees Heavy Put Option Activity Amid Bearish Market Sentiment
2025-12-02 12:00:07Divis Laboratories, a prominent player in the Pharmaceuticals & Biotechnology sector, has attracted significant attention in the options market with a surge in put option trading. The activity highlights a cautious stance among investors as the stock navigates recent price movements and sector dynamics.
Read MoreIs Divi's Lab. technically bullish or bearish?
2025-12-02 08:59:46Overview of Current Technical Trend As of 1 December 2025, Divi's Lab.'s technical trend shifted from a clear bullish stance to a mildly bullish one. This subtle change reflects a market environment where upward momentum persists but with tempered conviction. The stock's current price stands at ₹6,435.00, slightly below the previous close of ₹6,478.95, and well within its 52-week range of ₹4,941.70 to ₹7,077.70. Today's trading session saw a high of ₹6,517.95 and a low of ₹6,403.00, indicating a relatively narrow intraday range. Key Technical Indicators: Mixed Signals Examining the technical indicators in detail reveals a blend of bullish and mildly bearish signals across different timeframes: MACD (Moving Average Convergenc...
Read More
Divis Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals
2025-12-02 08:18:16Divis Laboratories, a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed review of its quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent changes in the company’s evaluation metrics, providing investors with a comprehensive understanding of its current standing.
Read More
Divis Laboratories Technical Momentum Shifts Amid Mixed Indicator Signals
2025-12-02 08:05:56Divis Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and mildly bearish signals across multiple timeframes. Recent market data reveals a subtle transition in price dynamics, with technical indicators offering a mixed perspective on the stock’s near-term trajectory.
Read MoreHow has been the historical performance of Divi's Lab.?
2025-12-01 23:05:19Revenue and Profit Growth Trends Over the seven-year period ending March 2025, Divi's Lab. has seen its net sales rise substantially from ₹4,946 crores in 2019 to ₹9,360 crores in 2025. Despite a slight dip in 2023, the overall trend reflects strong top-line expansion, with a compound annual growth rate (CAGR) exceeding 12%. Operating profit before depreciation and interest (PBDIT) has also shown resilience, reaching ₹3,320 crores in 2025, up from ₹2,027 crores in 2019. The operating profit margin, excluding other income, has fluctuated but remained healthy, peaking at over 43% in 2022 before settling at approximately 31.7% in 2025. Profit after tax (PAT) has mirrored this growth, climbing from ₹1,353 crores in 2019 to ₹2,191 crores in 2025. Earnings per share (EPS) ha...
Read More
Divis Laboratories Sees Notable Surge in Open Interest Amidst Market Activity
2025-11-26 15:00:15Divis Laboratories, a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a significant rise in open interest within its derivatives segment, signalling shifts in market positioning and investor sentiment. This development coincides with the stock’s recent outperformance relative to its sector and broader indices, prompting closer examination of volume patterns and potential directional bets.
Read More
Divis Laboratories Sees Shift in Market Assessment Amid Technical and Financial Developments
2025-11-25 08:15:11Divis Laboratories, a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation, reflecting changes across technical indicators, financial trends, valuation metrics, and overall quality parameters. This article analyses the factors influencing the recent shift in the company's assessment, providing investors with a comprehensive understanding of its current standing.
Read More
Divis Laboratories Technical Momentum Shifts Signal Market Interest
2025-11-25 08:06:10Divis Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, has exhibited notable shifts in its technical momentum, reflecting evolving market dynamics. Recent assessment changes highlight a transition towards a more bullish technical outlook, underpinned by mixed signals from key indicators such as MACD, RSI, and moving averages.
Read More
Divis Laboratories Sees Notable Surge in Open Interest Amidst Narrow Trading Range
2025-11-24 15:00:39Divis Laboratories, a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant rise in open interest in its derivatives segment, signalling a shift in market positioning. Despite a narrow trading range and subdued price movement, the surge in open interest alongside volume patterns suggests evolving investor sentiment and potential directional bets in the stock.
Read MoreBoard Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.
30-Jan-2026 | Source : BSEDivis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve the unaudited financial results for the quarter and nine months ended December 31 2025.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
03-Jan-2026 | Source : BSECertificate under Reg. 74(5) of SEBI (DP) Regulations 2018
Closure of Trading Window
31-Dec-2025 | Source : BSEIntimation of closure of Trading Window from January 01 2026.
Corporate Actions
No Upcoming Board Meetings
Divis Laboratories Ltd has declared 1500% dividend, ex-date: 25 Jul 25
Divis Laboratories Ltd has announced 2:10 stock split, ex-date: 03 Aug 07
Divis Laboratories Ltd has announced 1:1 bonus issue, ex-date: 23 Sep 15
No Rights history available